Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
A Phase II Study to examine the efficacy and safety of a new drug called Sevuparin on resolution of painful vaso-occlusive crisis in patients with sickle-cell disease. Modus Therapeutics AB Ongoing Sevuparin 3 TVOC01 KKUH
A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptorpositive/HER2-negative inoperable locally advanced or metastatic breast cancer – RIGHT Choice Study. Novartis Terminated ribociclib 2 CLEE011A3201C King Faisal Specialist Hospital and Research Center (Riyadh)
"A Phase II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cell transplantation" Novartis Completed ruxolitinib 2 CINC424G12201 KFSH&RC-R
A Phase Ib study to determine the safety and immunogenicity of the candidate Middle East Res-piratory Syndrome Coronavirus (MERS-CoV) vaccine ChAdOx1 MERS in healthy adult Middle Eastern volunteers KAIMRC Ongoing vaccine ChAdOx1 MERS 1b CT18/004/R NGHA-R
"A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults with Early Rheumatoid Arthritis who are Methotrexate Naive" Bristol-Myers Squibb Terminated Abatacept 3b IM101550 KFMC
A Phase 3b, open-labeled, randomized, parallel-group, multi-center study to evaluate the safety of novartis MenACWY Conjugate Vaccine when administered with routine infant Vaccinations to healthy Infants Novartis Completed Meningococcal ACWY Conjugate Vaccine 3b V59P23 KFMC
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) Astrazeneca Ongoing Trastuzumab Deruxtecan 3 D9670C00001 King Fahad Medical City (Riyadh)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/Week and 2.0 mg/kg/Every Other Week BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) BioMarin Pharmaceutical Inc. Completed BMN 110 3 MOR-004 KFSH & RC-R
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease (HOPE Kids 2) Sponsor (Global Blood Therapeutics, Inc.) Ongoing Voxelotor (GBT440) 3 GBT440-032 King Khalid University Hospital (Riyadh)
A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes Intarcia Therapeutics Completed ITCA 650 3 ITCA 650-CLP-105 NGHA-J
View 311 - 320 From 711